Literature DB >> 13989576

Iron excretion in thalassaemia major after administration of chelating agents.

R S SMITH.   

Abstract

Entities:  

Keywords:  ANEMIA, ERYTHROBLASTIC; CHELATING AGENTS; IRON METABOLISM

Mesh：

Substances：

Year:  1962        PMID： 13989576      PMCID： PMC1926818          DOI： 10.1136/bmj.2.5319.1577

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  5 in total

1.  The determination of iron in plasma or serum.

Authors:  T H BOTHWELL; B MALLETT
Journal:  Biochem J       Date:  1955-04       Impact factor: 3.857

2.  Studies on congenital hemolytic syndromes, IV. Gastrointestinal absorption of iron.

Authors:  M E ERLANDSON; B WALDEN; G STERN; M W HILGARTNER; J WEHMAN; C H SMITH
Journal:  Blood       Date:  1962-03       Impact factor: 22.113

3.  Evaluation of trisodium calcium diethylenetriaminepentacetate in iron storage disease.

Authors:  J L FAHEY; C E RATH; J V PRINCIOTTO; I B BRICK; M RUBIN
Journal:  J Lab Clin Med       Date:  1961-03

4.  The determination of iron in blood plasma or serum.

Authors:  W N RAMSAY
Journal:  Clin Chim Acta       Date:  1957-06       Impact factor: 3.786

5.  Generalized siderosis with fibrosis of liver and pancreas in Cooley's (Mediterranean) anemia; with observations on the pathogenesis of the siderosis and fibrosis.

Authors:  J T ELLIS; I SCHULMAN; C H SMITH
Journal:  Am J Pathol       Date:  1954 Mar-Apr       Impact factor: 4.307
  5 in total
  12 in total

Review 1.  Friedreich ataxia-update on pathogenesis and possible therapies.

Authors:  Max Voncken; Panos Ioannou; Martin B Delatycki
Journal:  Neurogenetics       Date:  2003-12-19       Impact factor: 2.660

Review 2.  IRON DEFICIENCY AND IRON OVERLOAD.

Authors: 
Journal:  Arch Dis Child       Date:  1965-08       Impact factor: 3.791

3.  Effect of Desferrioxamine and D.T.P.A. in Iron Overload.

Authors:  R M Bannerman; S T Callender; D L Williams
Journal:  Br Med J       Date:  1962-12-15

4.  Total management of thalassaemia major.

Authors:  B Modell
Journal:  Arch Dis Child       Date:  1977-06       Impact factor: 3.791

5.  Urinary iron excretion in thalassaemia after desferrioxamine administration.

Authors:  R Seshadri; J H Colebatch; R Fisher
Journal:  Arch Dis Child       Date:  1974-03       Impact factor: 3.791

6.  Survival and desferrioxamine in thalassaemia major.

Authors:  B Modell; E A Letsky; D M Flynn; R Peto; D J Weatherall
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-10

7.  Assessment of the developmental toxicity of deferoxamine in mice.

Authors:  M A Bosque; J L Domingo; J Corbella
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

8.  Inhibition of growth of Histoplasma capsulatum yeast cells in human macrophages by the iron chelator VUF 8514 and comparison of VUF 8514 with deferoxamine.

Authors:  S L Newman; L Gootee; V Stroobant; H van der Goot; J R Boelaert
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

Review 9.  A risk-benefit assessment of iron-chelation therapy.

Authors:  J B Porter
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.228

10.  Desferioximine induced Ototoxicity in Thalassemic patients.

Authors:  Dharam Vir; N K Panda; R K Marwaha
Journal:  Ann Neurosci       Date:  2010-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.